Pfizer breast cancer drug hits midstage study goal (Update)

February 3, 2014 by Linda A. Johnson

Drugmaker Pfizer Inc. said Monday that a midstage study of its experimental drug for advanced breast cancer, palbociclib, met the main goal.

The world's second-biggest drugmaker said the drug, combined with another medicine called letrozole, increased the time patients survived without tumors growing, compared with women just getting letrozole.

Shares of New York-based Pfizer jumped more than 4 percent early on and were up 38 cents, or 1.3 percent, at $30.79 in afternoon trading on a day when the broader markets fell sharply.

Analysts are closely watching palbociclib, which is for postmenopausal women with certain tumor characteristics found in about 60 percent of patients with advanced breast cancer. It's seen as a potential huge seller.

Credit Suisse analyst Vamil Divan wrote to investors Monday that he expects the drug to produce annual global sales of $2.9 billion in 2013.

"We believe our forecasts are likely conservative at this point," particularly if palbociclib turns out to also work on lung and blood cancers, Divan wrote in a research note.

He reiterated his "Outperform" rating for Pfizer, saying he likes the company's stock "as a multi-year restructuring story" due to possible bonuses from its pipeline of experimental drugs, "shareholder-friendly capital allocation" and a low share price.

Shares had languished in the teens for several years, then nearly doubled from $17.45 over the past 29 months—still well below the share price for Pfizer's major competitors.

Divan noted Pfizer's comments Monday could raise expectations the company could apply for and receive palbociclib approval a little earlier than expected.

Pfizer said it plans to release detailed results from the latest study, called PALOMA-1, at the American Association for Cancer Research meeting in San Diego in early April.

The company is now enrolling patients in a late-stage test of palbociclib. Last April, the Food and Drug Administration designated it a breakthrough therapy, a recognition that helps speed up the review needed for approval.

Explore further: Pfizer breast cancer drug gets breakthrough label

Related Stories

Pfizer breast cancer drug gets breakthrough label

April 10, 2013
Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.

Pfizer's 4Q net plunges on charges, sales decline

January 28, 2014
Drugmaker Pfizer said Tuesday that fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to siphon off revenue from former blockbuster ...

New drug combination delayed disease progression for subgroup of women with metastatic breast cancer

December 12, 2013
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of ...

Pfizer, Teva reach deal to allow generic Viagra

December 17, 2013
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

FDA adds most severe warning to Pfizer's Tygacil

September 30, 2013
Regulators are putting their harshest warning on Pfizer's antibiotic Tygacil, saying the drug is associated with an increased risk of death.

FDA OKs drug to treat hot flashes in menopausal women

October 4, 2013
(HealthDay)—Pfizer Inc. says it has gained U.S. approval for a drug designed to treat menopause-related hot flashes and potentially prevent osteoporosis in postmenopausal women who have a uterus.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.